Davis J L, Salmon J H, Papich M G
Clinical Pharmacology, Research Laboratories, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA.
J Vet Pharmacol Ther. 2005 Oct;28(5):425-31. doi: 10.1111/j.1365-2885.2005.00683.x.
The purpose of this study was to determine the pharmacokinetics and tissue fluid distribution of cephalexin in the adult horse following oral and i.v. administration. Cephalexin hydrate (10 mg/kg) was administered to horses i.v. and plasma samples were collected. Following a washout period, cephalexin (30 mg/kg) was administered intragastrically. Plasma, interstitial fluid (ISF) aqueous humor, and urine samples were collected. All samples were analyzed by high-pressure liquid chromatography (HPLC). Following i.v. administration, cephalexin had a plasma half-life (t(1/2)) of 2.02 h and volume of distribution [V(d(ss))] of 0.25 L/kg. Following oral administration, the average maximum plasma concentration (C(max)) was 3.47 mug/mL and an apparent half-life (t(1/2)) of 1.64 h. Bioavailability was approximately 5.0%. The AUC(ISF):AUC(plasma) ratio was 80.55% which corresponded to the percentage protein-unbound drug in the plasma (77.07%). The t(1/2) in the ISF was 2.49 h. Cephalexin was not detected in the aqueous humor. The octanol:water partition coefficient was 0.076 +/- 0.025. Cephalexin was concentrated in the urine with an average concentration of 47.59 microg/mL. No adverse events were noted during this study. This study showed that cephalexin at a dose of 30 mg/kg administered orally at 8 h dosage intervals in horses can produce plasma and interstitial fluid drug concentrations that are in a range recommended to treat susceptible gram-positive bacteria (MIC < or = 0.5 microg/mL). Because of the low oral bioavailability of cephalexin in the horse, the effect of chronic dosing on the normal intestinal bacterial flora requires further investigation.
本研究的目的是确定成年马经口服和静脉注射头孢氨苄后的药代动力学及组织液分布情况。给马静脉注射水合头孢氨苄(10mg/kg)并采集血浆样本。经过洗脱期后,经胃内给予头孢氨苄(30mg/kg)。采集血浆、间质液(ISF)、房水和尿液样本。所有样本均通过高压液相色谱法(HPLC)进行分析。静脉注射后,头孢氨苄的血浆半衰期(t(1/2))为2.02小时,分布容积[V(d(ss))]为0.25L/kg。口服给药后,平均最大血浆浓度(C(max))为3.47μg/mL,表观半衰期(t(1/2))为1.64小时。生物利用度约为5.0%。AUC(ISF):AUC(血浆)比值为80.55%,这与血浆中未结合蛋白的药物百分比(77.07%)相对应。ISF中的t(1/2)为2.49小时。房水中未检测到头孢氨苄。辛醇:水分配系数为0.076±0.025。头孢氨苄在尿液中浓缩,平均浓度为47.59μg/mL。本研究期间未观察到不良事件。本研究表明,马以30mg/kg的剂量、8小时间隔口服头孢氨苄可产生血浆和间质液药物浓度,该浓度处于推荐用于治疗敏感革兰氏阳性菌(MIC≤0.5μg/mL)的范围内。由于头孢氨苄在马体内口服生物利用度较低,长期给药对正常肠道细菌菌群的影响需要进一步研究。